London afternoon: Stocks dive deeper
29th Jun 2010 14:27
Expectations of a triple-digit fall on the Dow Jones index when Wall Street opens has added to London's woes. As in London, US investors are concerned that China's economy is not likely to grow at the rate previously anticipated. US based research group the Conference Board said overnight that its
Read moreLondon midday: Footsie waves goodbye to 5,000
29th Jun 2010 12:06
Footsie fell below 5,000 as mining shares tanked in the morning session on concerns that China's economy is not likely to grow at the rate previously anticipated. US based research group the Conference Board said its China leading economic index rose just 0.3% in April, a sharp revision down from
Read moreLondon open: Footsie slides lower
29th Jun 2010 08:56
London has followed US and Asian markets lower with only AstraZeneca in the blue at present. It was suggested as a possible takeover company for a US company by Standard & Poor's, along with BAE Systems and Balfour Beatty. US companies clearly are interested in UK assets judging from Emerson's 375
Read moreTuesday newspaper round-up: BP, AstraZeneca, Car industry
29th Jun 2010 06:43
Fresh tensions erupted between BP and the Kremlin last night after the British oil giant was forced to deny reports that Russia's Deputy Prime Minister had suggested its chief executive was on the verge of resignation. Just hours before Tony Hayward was due to meet Igor Sechin in Moscow for talks
Read moreAstraZeneca Pharma India Receives Delisting Offer From Founder
29th Jun 2010 04:48
MUMBAI (Dow Jones)--AstraZeneca Pharma India Ltd. (506820.BY) said Tuesday it has received a delisting offer from 90%-owner AstraZeneca Pharmaceuticals AB, sending its shares higher. The company didn't mention the delisting price, but said in a regulatory filing that its board will meet Tuesday
Read morePRESS RELEASE: CRESTOR® Patent Upheld By US Court
29th Jun 2010 00:06
WILMINGTON, Del., June 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 -- the '314 patent) is valid and enforceable. In its ruling, the court
Read moreUS HOT STOCKS: IDT, RehabCare, Smith & Wesson, Technitrol -2-
28th Jun 2010 22:01
IDT Corp. (IDT, $11.37, +$1.58, +16.14%), a company that only regained New York Stock Exchange compliance in April, made a splash at the exchange on Monday. The holding company, which focuses on telecommunications services but is turning more attention to energy services, rang the opening bell Monda
Read moreTeva Launches Generic Version Of AstraZeneca Breast-Cancer Drug
28th Jun 2010 19:55
DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) said it won approval from the U.S. Food and Drug Administration to commercially launch a generic version of AstraZeneca PLC's (AZN, AZN.LN) breast-cancer drug Arimidex. According to the generic-drug giant, AstraZeneca's
Read moreAstraZeneca Opens Drug Library To Malaria Researchers
28th Jun 2010 14:54
LONDON (Dow Jones)--U.K. drug maker AstraZeneca PLC (AZN.LN) said Monday it is giving researchers access to 500,000 compounds in its library in a drive to find new drugs for malaria. AstraZeneca said it entered an alliance with Medicines for Malaria Venture, a not-for-profit foundation set up to
Read moreStudies Show Potential Of New Type Of Diabetes Drug
26th Jun 2010 21:26
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES ORLANDO, Fla. (Dow Jones)--A new class of drugs being developed to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies released at a majo
Read moreStudies Show Potential Of New Type Of Diabetes Drug
26th Jun 2010 21:26
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES ORLANDO, Fla. (Dow Jones)--A new class of drugs being developed to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies released at a majo
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To -2-
26th Jun 2010 19:45
on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutic
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control in Patients With Type 2 Diabetes Inadequately Controlled With Insulin
26th Jun 2010 19:45
ORLANDO, Fla.--(BUSINESS WIRE)--June 26, 2010-- Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes pa
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To -2-
26th Jun 2010 19:45
Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, d
Read morePRESS RELEASE: Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
26th Jun 2010 19:45
/NOT FOR US MEDIA/ ORLANDO, FL, June 26 /CNW/ - Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes p
Read more